94. Rao JP, Geckeler KE (2011) Polymer nanoparticles: preparation techniques and size-control
parameters. Prog Polym Sci 36(7):887–913
95. Gao H et al (2012) Precise glioma targeting of and penetration by aptamer and peptide dualfunctioned nanoparticles. Biomaterials 33(20):5115–5123
96. Farokhzad OC, Jon S, Khademhosseini A, Tran T-NT, LaVan DA, Langer R (2004)
Nanoparticle-aptamer bioconjugates. Cancer Res 64(21):7668–7672
97. Kolishetti N et al (2010) Engineering of self-assembled nanoparticle platform for precisely
controlled combination drug therapy. Proc Natl Acad Sci 107(42):17939–17944
98. Tao W et al (2016) Polydopamine-based surface modification of novel nanoparticle-aptamer
bioconjugates for in vivo breast cancer targeting and enhanced therapeutic effects.
Theranostics 6(4):470–484
99. Seleci M, Ag Seleci D, Joncyzk R, Stahl F, Blume C, Scheper T (2016) Smart multifunctional
nanoparticles in nanomedicine. BioNanoMaterials 17(1–2):33–41
100. Aravind A et al (2012) Aptamer-labeled PLGA nanoparticles for targeting cancer cells. Cancer
Nanotechnol 3(1–6):1–12
101. Yu C et al (2011) Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer
drug to MUC1-positive cancer cells in vitro. PLoS One 6(9):1–8
102. Zhao N, Bagaria HG, Wong MS, Zu Y (2011) A nanocomplex that is both tumor cell-selective
and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnol 9:1–12
103. He X, Zhao Y, He D, Wang K, Xu F, Tang J (2012) ATP-responsive controlled release system
using aptamer-functionalized mesoporous silica nanoparticles. Langmuir 28
(35):12909–12915
104. Le Li L, Yin Q, Cheng J, Lu Y (2012) Polyvalent mesoporous silica nanoparticle-aptamer
bioconjugates target breast cancer cells. Adv Healthc Mater 1(5):567–572
105. Zhu CL, Lu CH, Song XY, Yang HH, Wang XR (2011) Bioresponsive controlled release
using mesoporous silica nanoparticles capped with aptamer-based molecular gate. J Am Chem
Soc 133(5):1278–1281
106. Chen H, Tian J, Liu D, He W, Guo Z (2017) Dual aptamer modified dendrigraft poly-l-lysine
nanoparticles for overcoming multi-drug resistance through mitochondrial targeting. J Mater
Chem B 5(5):972–979
107. Cohen BA, Bergkvist M (2013) Targeted in vitro photodynamic therapy via aptamer-labeled,
porphyrin-loaded virus capsids. J Photochem Photobiol B Biol 121:67–74
108. Farokhzad OC, Jon S, Khademhosseini A, Tran TT, Lavan DA, Langer R (2004) Advances in
brief nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Synthesis (Stuttg), pp 7668–7672
109. Xie X et al (2016) EpCAM aptamer-functionalized mesoporous silica nanoparticles for
efficient colon cancer cell-targeted drug delivery. Eur J Pharm Sci 83:28–35
110. Wang J et al (2012) Assembly of aptamer switch probes and photosensitizer on gold nanorods
for targeted photothermal and photodynamic cancer therapy. ACS Nano 6(6):5070–5077
111. Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Hamblin MR (2013) Low-level laser
(light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg 32
(1):41–52
112. Agostinis P, Berg K, Cengel K et al (2011) Photodynamic therapy of cancer: an update. Ca
Cancer J Clin 61(4):250–281
113. Sinha N, Member S, Yeow JT (2005) Carbon nanotubes for biomedical applications (carbon
nanostructures). IEEE Trans Nanobioscience 4(2):180–195
114. Nair BG, Nagaoka Y, Morimoto H, Yoshida Y, Maekawa T, Kumar DS (2010) Aptamer
conjugated magnetic nanoparticles as nanosurgeons. Nanotechnology 21(45)
115. Weinstein JS et al (2010) Superparamagnetic iron oxide nanoparticles: diagnostic magnetic
resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 30(1):15–35
116. Mirau PA, Smith JE, Chávezchávez JL, Hagen JA, Kelley-Loughnane N, Naik R (2018)
Structured DNA aptamer interactions with gold nanoparticles. Langmuir 34:18
192
A. Eilers et al.
parameters. Prog Polym Sci 36(7):887–913
95. Gao H et al (2012) Precise glioma targeting of and penetration by aptamer and peptide dualfunctioned nanoparticles. Biomaterials 33(20):5115–5123
96. Farokhzad OC, Jon S, Khademhosseini A, Tran T-NT, LaVan DA, Langer R (2004)
Nanoparticle-aptamer bioconjugates. Cancer Res 64(21):7668–7672
97. Kolishetti N et al (2010) Engineering of self-assembled nanoparticle platform for precisely
controlled combination drug therapy. Proc Natl Acad Sci 107(42):17939–17944
98. Tao W et al (2016) Polydopamine-based surface modification of novel nanoparticle-aptamer
bioconjugates for in vivo breast cancer targeting and enhanced therapeutic effects.
Theranostics 6(4):470–484
99. Seleci M, Ag Seleci D, Joncyzk R, Stahl F, Blume C, Scheper T (2016) Smart multifunctional
nanoparticles in nanomedicine. BioNanoMaterials 17(1–2):33–41
100. Aravind A et al (2012) Aptamer-labeled PLGA nanoparticles for targeting cancer cells. Cancer
Nanotechnol 3(1–6):1–12
101. Yu C et al (2011) Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer
drug to MUC1-positive cancer cells in vitro. PLoS One 6(9):1–8
102. Zhao N, Bagaria HG, Wong MS, Zu Y (2011) A nanocomplex that is both tumor cell-selective
and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnol 9:1–12
103. He X, Zhao Y, He D, Wang K, Xu F, Tang J (2012) ATP-responsive controlled release system
using aptamer-functionalized mesoporous silica nanoparticles. Langmuir 28
(35):12909–12915
104. Le Li L, Yin Q, Cheng J, Lu Y (2012) Polyvalent mesoporous silica nanoparticle-aptamer
bioconjugates target breast cancer cells. Adv Healthc Mater 1(5):567–572
105. Zhu CL, Lu CH, Song XY, Yang HH, Wang XR (2011) Bioresponsive controlled release
using mesoporous silica nanoparticles capped with aptamer-based molecular gate. J Am Chem
Soc 133(5):1278–1281
106. Chen H, Tian J, Liu D, He W, Guo Z (2017) Dual aptamer modified dendrigraft poly-l-lysine
nanoparticles for overcoming multi-drug resistance through mitochondrial targeting. J Mater
Chem B 5(5):972–979
107. Cohen BA, Bergkvist M (2013) Targeted in vitro photodynamic therapy via aptamer-labeled,
porphyrin-loaded virus capsids. J Photochem Photobiol B Biol 121:67–74
108. Farokhzad OC, Jon S, Khademhosseini A, Tran TT, Lavan DA, Langer R (2004) Advances in
brief nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Synthesis (Stuttg), pp 7668–7672
109. Xie X et al (2016) EpCAM aptamer-functionalized mesoporous silica nanoparticles for
efficient colon cancer cell-targeted drug delivery. Eur J Pharm Sci 83:28–35
110. Wang J et al (2012) Assembly of aptamer switch probes and photosensitizer on gold nanorods
for targeted photothermal and photodynamic cancer therapy. ACS Nano 6(6):5070–5077
111. Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Hamblin MR (2013) Low-level laser
(light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg 32
(1):41–52
112. Agostinis P, Berg K, Cengel K et al (2011) Photodynamic therapy of cancer: an update. Ca
Cancer J Clin 61(4):250–281
113. Sinha N, Member S, Yeow JT (2005) Carbon nanotubes for biomedical applications (carbon
nanostructures). IEEE Trans Nanobioscience 4(2):180–195
114. Nair BG, Nagaoka Y, Morimoto H, Yoshida Y, Maekawa T, Kumar DS (2010) Aptamer
conjugated magnetic nanoparticles as nanosurgeons. Nanotechnology 21(45)
115. Weinstein JS et al (2010) Superparamagnetic iron oxide nanoparticles: diagnostic magnetic
resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 30(1):15–35
116. Mirau PA, Smith JE, Chávezchávez JL, Hagen JA, Kelley-Loughnane N, Naik R (2018)
Structured DNA aptamer interactions with gold nanoparticles. Langmuir 34:18
192
A. Eilers et al.